Baiji Shenzhou announced its financial results for the second quarter of 2020.

Read: Revenue for the three months ended June 30, 2020 was $65.64 million . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "We have come a long way since the second quarter , when we have approved three indications ® beseen in China , and eight new drug listingapplications for Beze®an ® , Baiyueze ® and Pamipali have been accepted in China , the European Union , Australia and Israel , " said John V. Oyler , founder , chief executive officer and chairman of the
.
revenue hit a new high of about $66 million in the quarter, driven by the company's commercialization team, mainly from our recently launched independent research and development products. Mr. o'Reilly,
," added Mr. O'Reilly, "The company's recent successful direct issuance of a net income of approximately $2.07 billion will significantly accelerate the development of existing rich research and development pipelines, further expand our portfolio in the field of oncology and other diseases, and continue to build in-house capabilities and operations to serve more patients worldwide."
for the rest of 2020 and 2021, we look forward to expanding the business opportunities of our products by being approved in new indications and geographic markets and increasing our business phase portfolio to 11.
" recent business highlights and expected milestones of commercial operations of the Baiyue Zeze ® (Zebtini) in June approved by the State Drug Administration (NMPA) for the treatment of adult chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients who have previously received at least one treatment, as well as for patients with adult cell lymphoma (MCL) who have previously received at least one treatment. Within 12 days to complete the commercial listing of these two indications in China, The Baizean ® (Terelli Zhumono) was approved by NMPA in April for the treatment of patients with local advanced or metastatic urethra skin cancer (a type of bladder cancer) and completed the commercial listing in China on July 1st, launching the China Commercial Listing for the treatment of patients with bone cell tumor (GCTB) by Angarve ® (Disuzumab).
Angarve ® was approved by NMPA for the indications in May 2019 and subsequently commercialized by Amin.
This is the first Amgen product to be commercially listed by Baiji Shenzhou in China in January 2020 after the global oncology strategic cooperation was reached in January 2020, the first product revenue of the three months to June 30, 2020 was $65.64 million, although ABRAANE has been discontinued in China since March and recalled, the total product revenue is still 13% YoY, mainly from the company's independent research and development products Bezean an, mainly from the company's independent research and development products. ® and Peripay zee ® after the commercial listing of the revenue Beazean ® for the treatment of classic Hodgkin's lymphoma (cHL), Bacauze ® for the treatment of CLL/SLL and Angarve ® for the treatment of GCTB in Hainan Province's supplementary medical drug catalog research and development project Buduze ® (Zebtinib): a small molecule designed to maximize target occupancy, minimize off-target effect brutonine kinekine (BTK) inhibitors.
,
, the ® has been approved in the United States for the treatment of adult MCL patients who have previously received at least one treatment, and in China has been approved for the treatment of two indications: adult CLL/SLL patients who have previously received at least one treatment, and adult MCL patients who have previously received at least one therapy.
currently, global development projects for the ® of Bellepayze are on the way to the approval of more phytopathy® for patients with at least one previous treatment, OR a first-line treatment for WM patients who have previously received at least one treatment, or as a first-line treatment for wm patients who are not suitable for chemotherapy, and the European Medicines Agency (EMA) is accepted by the European Medicines Agency (EMA) to announce the online scientific meeting® of the American Society of Clinical Oncology (ASCO) in 2020 ASPEN3 Clinical Trial Data for the Treatment of WM Patients signed an exclusive agency distribution agreement with Medison Pharma in Israel and announced that the application for the listing of a new drug (NDA) for the treatment of MCL patients who have previously received at least one treatment has been accepted in Israel and submitted to the Australian Drug Administration (TGA) two Penteligible ® NDA, respectively, for relapsed/difficult (R/R) MCL and WM, and received the ®. The milestone is expected to be submitted in China in 2020 for the treatment of WM patients New Indications Market Application (sNDA) as early as the second half of 2020 to announce the main results of the Pyne-Ze® compared phenyamostincombintoxaxtox to treat patients with primary treatment of CLL or SLL SEQUOIA clinical trial (NCT0333363333) in 2020 with the U.S. Food and Drug Administration (FDA) on the treatment of patients with the use of Bacchus ® Clinical trial (NCT03053440) data discussion in 2020 to complete the baiyue ® compared ibtinib for the treatment of R/RCLL or SLL patients ALPINE Phase 3 clinical trial (NCT03734016) extended patient stake in baczean ® (terreiweight monosai), a design designed to avoid binding to macrophage receptors, for the detection of receptor singular PD-1.
Bezean ® has been approved in China for the treatment of cHL patients who have previously received at least two treatments, and patients with locallate or metastatic PD-L1 highly expressed urinary skin cancer who have undergone platinum-containing chemotherapy failures including progression of new or auxiliary chemotherapy within 12 months.
currently, global development projects for The beaan ® are on going forward, and for more indications, nMPA has been approved for beta'an ® combined chemotherapy for the treatment of patients with advanced non-squamous non-small cell lung cancer (NSCLC) and nMPA has accepted Bezean ® SNDA, the most common type of liver cancer used to treat patients with previously treated non-removable hepatocellular carcinoma (HCC), was announced at the 2020 ASCO Online Scientific Conference the results of the stage 3 clinical outcome of The Bzean ® combined standard chemotherapy for patients with terminal squamous NSCLC.
this data has been included in the SNDA under NMPA review in China to launch a Beaxean ® combined chemotherapy compared with placebo combined chemotherapy for the treatment of patients with excision II or IIIA NSCLC patients (NCT04379635) patients completed in the treatment of dismatching repair defects (dMMR) or hypersate instability (MSI-H) solid tumor patients in critical 2 clinical trials (NCT0373666) 889) Patient entry and Huang Pharma signed a clinical development cooperation agreement with Huang Medicine to conduct clinical trials in the United States, Europe, China and Australia to evaluate the safety, tolerance and effectiveness of the Beazen ® and Huang pharmaceutical drugs - Aiyout ® (Furantenib) and Sofantinib for the treatment of a number of solid tumors® is expected to be announced in 2020 at the European Society® of Oncology (ESMO) annual meeting. Combined chemotherapy as a phase 3 clinical trial of advanced non-scaly NSCLC first-line therapy (NCT03663205) data.
data has been included in the SNDA under NMPA review and published in 2020 or early 2021® in a Phase 3 clinical trial for the use of Bidosithalathasin for the treatment of patients with second- or third-line NSCLC (NCT03358) 875) and Bezean ® Compared Chemotherapy to Patients with Second-Line Advanced Esophageal Squay Cell Carcinoma (ESCC) Major Results of the Global Phase 3 Clinical Trial (NCT03430843) Pamepali: A High Selective ParParP1 and PARP2 small molecular inhibitors announced that NMPA has received Pamipali for the treatment of advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has previously received at least two lines of chemotherapy and has been present with a disease-causing or suspected germbrca mutation. The patient's NDA and its inclusion in the priority review Of pamperie is expected to announce at the 2020 ESMO online annual meeting that Pamipali will be used to treat advanced ovarian cancer, which has previously received at least two lines of chemotherapy and has a disease-causing or suspected germcell BRCA mutation. 1/2 clinical trial (NCT03333915) in patients with fallopian tube cancer or primary peritoneal cancer.
the data has been included in the NDA under nMPA review in 2020 or the first half of 2021 to publish Pamipali as a platinum-sensitive recurrent ovarian cancer (OC) patient maintenance treatment phase 3 clinical trial (NCT03519230) key results of early clinical development projects continue to drive the company's independent research and development of early pipeline sourcing processes, including BGB-A1217 (a joint with Bezean ® for cancer is in the 1/2 phase Clinically developed TIGIT monoclonal antibodies), BGB-11417 (a BCL-2 inhibitor for cancer in phase 1/2 clinical development), BGB-A445 (a non-ligand anti-OX40 monoclonal antibody jointly developed in Phase 1 clinicaldevelopment with Bezean ®), BGB-10188 (a ® for cancer and Bezee ® or Bezean. Joint phase 1 clinically developed PI3K inhibitors) and BGB-15025 (a PREclinical lysis for cancer HPK1 inhibitor) by TIGIT monoclonal antibody BGB-A1217 joint BBIAin ® phase 1 clinical trial data for patients with advanced solid tumors identified the recommended dose partnership Zanidatamab (ZW25): a phase 2 trial ™ dual antibody, in cooperation with Zyme Phase 2 clinical development initiated the production technology transfer Zanidatamab to the Guangzhou biological drug production base in Baiji Shenzhou expected the milestone event to support the planned clinical development of the first-line HER2-positive gastric esophageal adenocarcinoma (late 2020 and early 2021) clinical patient sentry in the study of the RAF dipolymer inhibitors. MapKure, currently developed by MapKure, jointly owned by Baiji Shenzhou and SpringWorks Therapeutics, has launched Phase 1 clinical trial (NCT04249843) in patients in the U.S. and Australia for the treatment of patients with advanced or refractive solid tumors (NCT04249843) and is expected to announce the milestone in 2021 Preliminary data production base completed the first phase of the Guangzhou biopharmaceutical production base equipment verification and production process verification started the Guangzhou biopharmaceutical production base phase 2 expansion project, to large-scale upgrade of production capacity and the introduction of new production technology platform, is expected to complete by the end of 2020 the impact of the new crown pneumonia outbreak and response measures Company expects the new crown pneumonia virus (COVID-19) caused by the world health crisis will continue to have a certain negative impact on its business, including commercial sales, drug communication and inspection, Patient recruitment and patient involvement in clinical trials.
While the impact of the outbreak on the company's second-quarter operations has diminished compared to the first quarter of 2020, the impact of the global pandemic on China and globally remains uncertain.
Is working to reduce the delays and disruptions caused by the outbreak and continues to work on other developments in line with globally established commercialization, pharmaceutical and clinical development targets to complete a registered direct issue of $145,828,979 shares per share (equivalent to $185 per American Depositary Share "ADS") with total revenue of approximately $2.08 billion, net income after issuance fees. $2.07 billion and AssemblyBiosciences in its research and development pipeline for three clinical phase sized phase hepatitis B virus inhibitors for the treatment of chronic hepatitis B virus infection - ABI-H0371, ABI-H2158 and ABI-H3733 - in China a licensing cooperation agreement appointed Dr. Angus Grant as Chief Business Executive, responsible for business development, alliance management, to help promote external innovation and investment, Cash, cash equivalents, restricted funds and short-term investments for the second quarter of 2020, led by The Company's global development strategy, were $3.16 billion as of June 30, 2020, compared with holdings of $3.38 billion on March 31, 2020 and $985.5 million held on December 31, 2019.
cash holdings as at June 30, 2020 excluding approximately $2.07 billion in registered direct issuance of net proceeds to specific existing investors as of July 15, 2020, amounted to $263 million in cash from operating activities for the three months ended June 30, 2020, and capital expenditures of 3 $2.61 million, compared to $46.1 million for operating activities and $21.45 million in revenue for the three months ended June 30, 2020, compared to $243.35 million for the same period in 2019. the decrease in
's total revenue year-on-year was mainly attributable to the lack of co-operation revenue since the termination of the Baizean ® cooperation agreement with New Base in June 2019 and the decrease in sales since NMPA suspended ABRAXANE in China in March 2020, but Part of this offset revenue of $65®.64 million for the three months ended June 30, 2020, compared with $58.14 million for the same period in 2019, in the same period in which The Company's product revenue was offset by revenue from The ® in China and the U.S.
product revenue includes: - Perzeon ® product revenue in China was $29.42 million - this is the first full quarter of sales activity since The Baizean ® went commercial in March 2020 - Anderbyer ® revenue in the U.S. and China was $6.97 million, including the amount of inventory used by distributors to create inventory after approval in China in June 2020 ® and Vidasa ® product revenue in China was $29.01 million, compared to $23.41 million for the same period in 2019 - $240,000 for ABRAXANE products, including accrued rebates from the March 2020 discontinuation and product recalls, and compared with the same period in 2019.